Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China
· Delayed Price · Currency is CNY 27.50
+1.05 (3.97%)
Apr 29, 2026, 3:04 PM CST
SHE:300878 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 225.27 | 347.01 | 514.56 | 529.41 | 631.18 | Upgrade
|
| Other Revenue | - | 4.19 | 5.07 | 3.03 | 1.77 | Upgrade
|
| Revenue | 225.27 | 351.2 | 519.62 | 532.44 | 632.95 | Upgrade
|
| Revenue Growth (YoY) | -35.86% | -32.41% | -2.41% | -15.88% | 1.64% | Upgrade
|
| Cost of Revenue | 155.29 | 223.4 | 257.69 | 219.08 | 204.38 | Upgrade
|
| Gross Profit | 69.98 | 127.8 | 261.93 | 313.36 | 428.57 | Upgrade
|
| Selling, General & Admin | 147.61 | 261.73 | 249.42 | 230.39 | 294.74 | Upgrade
|
| Research & Development | 9.37 | 14.19 | 42.8 | 39.32 | 37.02 | Upgrade
|
| Other Operating Expenses | -1.4 | 10.23 | 1.07 | -17.9 | 4.8 | Upgrade
|
| Operating Expenses | 155.58 | 289.32 | 281.83 | 259.12 | 344.96 | Upgrade
|
| Operating Income | -85.6 | -161.53 | -19.9 | 54.24 | 83.62 | Upgrade
|
| Interest Expense | - | -9.34 | -9.45 | -5.41 | -2.16 | Upgrade
|
| Interest & Investment Income | - | 94.26 | 14.56 | 17.04 | 5.55 | Upgrade
|
| Other Non Operating Income (Expenses) | -13.79 | -0.07 | -0.09 | -0.16 | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -99.38 | -76.67 | -14.88 | 65.71 | 86.91 | Upgrade
|
| Impairment of Goodwill | - | -7.76 | -0.14 | -0.22 | -0.08 | Upgrade
|
| Gain (Loss) on Sale of Investments | -12.48 | - | 4.56 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.99 | -0.47 | -0.01 | -0.63 | 0.07 | Upgrade
|
| Asset Writedown | -95.62 | -76.26 | -0.52 | -0.18 | -0.02 | Upgrade
|
| Other Unusual Items | - | 2.89 | 4.3 | -1.52 | 13.16 | Upgrade
|
| Pretax Income | -208.48 | -158.28 | -6.68 | 63.15 | 100.03 | Upgrade
|
| Income Tax Expense | 21.26 | -13.4 | 0.42 | 13.67 | 3.48 | Upgrade
|
| Earnings From Continuing Operations | -229.73 | -144.88 | -7.1 | 49.48 | 96.55 | Upgrade
|
| Minority Interest in Earnings | 2.39 | -2.55 | -1.85 | -0.67 | -0.05 | Upgrade
|
| Net Income | -227.34 | -147.43 | -8.95 | 48.81 | 96.5 | Upgrade
|
| Net Income to Common | -227.34 | -147.43 | -8.95 | 48.81 | 96.5 | Upgrade
|
| Net Income Growth | - | - | - | -49.42% | -28.95% | Upgrade
|
| Shares Outstanding (Basic) | 145 | 143 | 149 | 144 | 144 | Upgrade
|
| Shares Outstanding (Diluted) | 145 | 143 | 149 | 144 | 144 | Upgrade
|
| Shares Change (YoY) | 1.17% | -4.09% | 3.96% | -0.32% | 19.60% | Upgrade
|
| EPS (Basic) | -1.57 | -1.03 | -0.06 | 0.34 | 0.67 | Upgrade
|
| EPS (Diluted) | -1.57 | -1.03 | -0.06 | 0.34 | 0.67 | Upgrade
|
| EPS Growth | - | - | - | -49.25% | -40.59% | Upgrade
|
| Free Cash Flow | -0.08 | -154.1 | -81 | -28.21 | -238.84 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -1.08 | -0.54 | -0.20 | -1.66 | Upgrade
|
| Dividend Per Share | - | 0.140 | 0.250 | - | 0.300 | Upgrade
|
| Dividend Growth | - | -44.00% | - | - | -46.00% | Upgrade
|
| Gross Margin | 31.06% | 36.39% | 50.41% | 58.85% | 67.71% | Upgrade
|
| Operating Margin | -38.00% | -45.99% | -3.83% | 10.19% | 13.21% | Upgrade
|
| Profit Margin | -100.92% | -41.98% | -1.72% | 9.17% | 15.25% | Upgrade
|
| Free Cash Flow Margin | -0.04% | -43.88% | -15.59% | -5.30% | -37.73% | Upgrade
|
| EBITDA | -22.72 | -103.25 | 26.75 | 84.04 | 97.65 | Upgrade
|
| EBITDA Margin | -10.08% | -29.40% | 5.15% | 15.78% | 15.43% | Upgrade
|
| D&A For EBITDA | 62.88 | 58.28 | 46.65 | 29.8 | 14.03 | Upgrade
|
| EBIT | -85.6 | -161.53 | -19.9 | 54.24 | 83.62 | Upgrade
|
| EBIT Margin | -38.00% | -45.99% | -3.83% | 10.19% | 13.21% | Upgrade
|
| Effective Tax Rate | - | - | - | 21.64% | 3.48% | Upgrade
|
| Revenue as Reported | - | 351.2 | 519.62 | 532.44 | 632.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.